MindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market

Reuters

09/22

<a href="https://laohu8.com/S/HYFT">MindWalk Holdings Corp</a>. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market

MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922510586) on September 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569786723"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569786723\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569786723?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569786723","market":"fut","top_or_hot":-1,"title":"MindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HYFT\">MindWalk Holdings Corp</a>. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922510586) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-22 19:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HYFT\">MindWalk Holdings Corp</a>. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922510586) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HYFT","symbol_name":"MindWalk Holdings Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL4CdbJ3:1","article_id":"2569786723","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569786723","pubTimestamp":1758538940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HYFT":"MindWalk Holdings Corp","BK4121":"生命科学工具和服务"},"translate_title":"MindWalk Holdings Corp.推出人工智能驱动的抗衰老和长寿双途径GLP-1方案，瞄准60B美元市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HYFT":0.9},"content_text":"MindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market\n    \n\n        MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922510586) on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}